li001

Ten-year follow-up data from the phase 2 NCT01500733 trial showed that continuous treatment with Ibrutinib provides long-term disease control for patients with high-risk chronic lymphocytic leukemia (CLL), including those with TP53 abnormalities. Among 84 patients, median progression-free survival reached 7.2 years, while median overall survival was not yet reached. The 10-year progression-free survival rate was […]

The phase 3 PSMAddition trial showed that adding Lutetium Lu 177 vipivotide tetraxetan to standard androgen-deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) significantly improved prostate-specific antigen (PSA) responses in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC). The study included 1,144 patients, most with high tumor burden and bone metastases. Researchers previously

Treatment for cutaneous T-cell lymphoma (CTCL) is increasingly tailored to disease stage and location. Early-stage skin-only disease is often treated with phototherapy, while advanced disease may require systemic therapies such as romidepsin, pralatrexate, or Brentuximab vedotin. A key option for advanced CTCL is Mogamulizumab-kpkc, particularly for patients with high blood involvement or Sezary syndrome. In

A large real-world study in Japan has confirmed the long-term safety and effectiveness of Darbepoetin Alfa for treating anemia in patients with myelodysplastic syndromes (MDS). The 5-year post-marketing surveillance study followed 1,834 patients across 460 medical centers, providing much broader evidence than the original 2014 approval trial, which included only 52 patients. Researchers found that

The global phase 3 TroFuse-005 trial evaluated Sacituzumab Tirumotecan in 776 patients with advanced or recurrent endometrial cancer or carcinosarcoma whose disease had progressed after platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy. The study compared the drug with physician’s choice chemotherapy, including doxorubicin or paclitaxel. Researchers reported that Sacituzumab Tirumotecan significantly improved both overall survival and progression-free